A closely watched experimental drug for Lou Gehrig’s disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness.
You may also be interested in:
A cap-and-invest strategy to cut transportation-related carbon emissions could provide substantial health benefits to children in New York City, with greater benefits among Black and [...]
Playgrounds are fun and can provide a great opportunity for exercise and family togetherness. But did you know that youths age 17 and younger are [...]
According to a new modeling study, published in JAMA Pediatrics, the number of children estimated to have experienced the death of a parent or caregiver [...]